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Journalist:
Aren’t you afraid of not feeling human after the implantation of
the deep brain stimulation electrodes to treat your resistant depression?
Patient:
When I was suffering from treatment-resistant depression I was not feeling human!
(A patient of Dr. Helen Mayberg treated with Deep Brain Stimulation).
INTRODUCTION
In this opinion article, we humbly propose a new viewpoint on the etiopathogenesis of depression.
We base the model on our interpretation of selected recent neurophysiological findings, mainly
regarding Deep Brain Stimulation (DBS) to treat Parkinson’s Disease and also DBS to treat
Treatment-Resistant Depression (TRD). We coin the idea a mental kindling-like mechanism.
However, future clinical research, possibly complemented with human laboratory research or
animal experiments, will be needed to test the validity of our proposed model. On the current
manuscript framework, following the first and introductory section, we will set the stage by
presenting selected studies and insights mainly from DBS to treat TRD and PD, on the second
and middle section. Finally, we will discuss the proposed viewpoint on the third and last section of
the present work.
SELECTED NEUROPHYSIOLOGICAL STUDIES AND INSIGHTS
FROM DBS TO TREAT TREATMENT-RESISTANT DEPRESSION
AND PARKINSON’S DISEASE
DBS as a Therapy for PD
DBS was first introduced to medical practice by Benabid et al. (1). They discovered that high-
frequency stimulation of the thalamus diminished tremor. Later, guided by the neurophysiological
studies of Bergman et al. on the neural circuits involved in PD (2), Benabid stimulated the
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subthalamic nucleus with high-frequency current and achieved
significant improvement of PD symptoms (3). PD has been
linked to degeneration of dopaminergic neurons in the
substantia nigra (4), which eventually results in an abnormal
neuronal activity in the basal ganglia circuitry. This abnormal
activity is characterized by synchronous bursts, which resemble
epileptiform activity (5). These abnormal bursts affect the activity
in the thalamus and cortical areas, causing the symptoms of
PD (4). DBS has a therapeutic effect on PD because it disrupts
the abnormal bursting in the basal ganglia—corticothalamic
loops (6).
DBS as a Therapy for Depression
In 2005, Mayberg’s group reported that DBS was effective for
the treatment of patients with depression who were resistant
to medication and/or electroconvulsive therapy (ECT) (7). The
idea of such treatment was based on neuroimaging studies
that revealed, in some patients with depression, abnormal
hyperactivity of the subcallosal cingulate cortex (SCC) also
known by area 25 of Broadman (BA25) or subgenual cingulated
(Cg25). Mayberg et al. hypothesized that this hyperactivity
detected in neuroimaging studies could be reduced by DBS.
Indeed, DBS of the area 25 reduced depression symptoms in
patients with abnormal neural activity (7). After this work, other
studies have been published regarding the stimulation of area 25
of Broadman in depression making this area the most targeted
in DBS for treatment-resistant depression (7–12). The lateral
habenula is another area targeted in depression. It has been
reported that the hyperactivity in this area can be ameliorated
with DBS (13). Contrarily to the hyperactivation in the area 25
of Broadman and in the lateral habenula, there is hypoactivity
in the nucleus accumbens (NAcc) that can be reverted by DBS
in patients with treatment-resistant depression (14, 15). Other
areas that have been stimulated in DBS are the ventral capsule
and ventral striatum (16, 17), the internal capsule (18), the
medial forebrain bundle (19), and the inferior thalamic peduncle
(20). As it can be noted, there are different areas with distinct
type of neural activity (hypo/hyperactivity) in treatment-resistant
depression and DBS with high frequency stimulation can bring
those activity to normal.
DBS Mechanisms
The exact mechanisms by which DBS works are not fully
understood. In particular, it may seem paradoxical that
DBS inhibits neural activity in the stimulated area instead
of stimulating the neurons, therefore acting in a similar
way to an ablation (6). One explanation for the inhibitory
effect of DBS is that in the thalamus it induces a release
of inhibitory neurotransmitters such as the homeostatic
neuromodulator adenosine that causes a decrease in the
excitatory neurotransmission and a reduction of tremor via
Adenosine A1 receptors activation (21, 22). Inhibition is not
the only mechanism by which DBS alleviates symptoms of PD
and depression. Other mechanisms have been suggested and
reviewed elsewhere (23), such as replacement of pathological
bursting by neuronal patterns driven by DBS (24).
The correction of abnormal brain activity is another proposed
DBS mechanism of action. Since, on the one hand, there is
abnormal brain oscillation in PD (25) that is similar to the
neural activity observed in some models of seizures and epilepsy
(26, 27), and on the other hand, it has also been reported
abnormal brain oscillation between some areas in depressive
animals, it was considered that, at least in part, some abnormal
epileptiform oscillation might be an electrophysiologic trait of
some neurologic and psychiatric disorders. The origin of some
abnormal brain oscillations is at the core of our proposedmental
kindling-like mechanism and it will be addressed in the third part
of the current manuscript.
DBS Works by Stimulating a Specific Brain
Area. Why Do Therapies Such as
Electroconvulsive Therapy (ECT) and
Repetitive Transcranial Magnetic
Stimulation (rTMS) Do Not Target a
Specific Brain Area?
DBS of the subcallosal cingulated cortex (SCC) is effective in
the treatment of depression. However, a patient-personalized
protocol must be applied in order to be effective. Neuroimaging
and electrophysiological studies during DBS surgery allow the
determination of the exact andmost adequate area to stimulate. It
seems that SCC resembles a crossroad of different projections and
the best effect is achieved by stimulating the exact crossing point
(28). DBS targets specific areas that are functionally impaired
in Depression. Some therapies such as the well-known ECT
and the more recent TMS (initially applied to treat depression
and then extended to other psychiatric disorders) (29–31), act
in broader way. The duration of the effect varies among the
different approaches: DBS only works when the stimulation
is on, ECT’s effects are more sustained (although requiring
maintenance sessions), while TMS requires multiple sessions
during weeks before achieving clinical results. The reason for
these discrepancies is not known. A possible explanation could
be that unlike DBS, that is more efficient locally, the other
techniques could simultaneously modulate several regions and
be more effective targeting the systemic/circuitries changes or, at
least in part, the broad stimulation can reaches themore deep and
specific areas through white matters pathways.
Other Selected Neuroanatomical and
Neurophysiological Findings Relevant to
Our Viewpoint
Psychiatric or mental disorders are some of the most difficult
diseases to understand. Unlike the diseases that can be explained
by a single gene mutation, specific lesions or microorganisms,
mental disorders usually have multiple causes. As it has been
stated in this paper, there are several areas with distinct neural
activities (hypo/hyperactivity) that can be targeted in DBS for
depression. Besides the local abnormal neural activity observed
in neuroimaging techniques, there are abnormal oscillations
between different regions that can be recorded with non-
invasive electrophysiological tools and that might be used as
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FIGURE 1 | (A) A schematic of the hypothesis of the mental kindling-like mechanism in the etiopathogenesis of Depression. Repetitive sad life events, whether mild,
moderate, or severe cause not only repetitive conscious thoughts and/or feelings, but also recall memories of sad feelings and thoughts. This pattern starts as a
conscious process but can later become an independent or involuntarily process that can self-perpetuate and eventually cause the mental kindling-like mechanism.
The mechanism may cause the depletion of serotonin and/or work as a trigger to dysregulate the neural nucleus and networks of emotion, resulting in the
hypofunction/hyperfunction of different areas as well as abnormal communication between areas. (B) An hypothetical integrative physiopathological perspective of
treatment-resistant major depression. A change in the neuronal activity of a brain region associated with depressive symptoms, decreased monoamine
neurotransmission and abnormal neural activity caused, at least in part, by a possible mental kindling-like mechanism triggered by repetitive adverse live events in
patients with genetic and/or psychological predisposition to depression. Due to the complexity and the multifactorial causes of depression, a single perspectives are
not enough to understand the mechanisms of this disorder. A global and a more integrative perspective with the contribution of different disciplines can help
understanding the mechanisms of depression.
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potential biomarkers to evaluate neuromodulation success (32).
To simplify our perspective about depression, we will focus on
a particular brain area, but we consider that the mechanism we
propose can, possibly, be applied to different areas of the brain.
Several studies suggest that the chronic hyperactivation of area
25 is one of the neural mechanisms of depression. Functional
neuroanatomy studies demonstrated that simply thinking about
sad life events causes hyperactivity of the area 25 (33). This
hyperactivity can be reduced by several types of treatment:
selective serotonin reuptake inhibitor (8), transcranial magnetic
stimulation (TMS) (34) and electroconvulsive therapy (ECT)
(35). Several studies reported that depression is a multifactorial
disease. From a pragmatic point of view, in psychiatry we observe
a frequent pattern in clinical practice: a typical depressive patient
has familiar history of depression or other mental illness, and
has experienced one or few severe life stress, or accumulated
many mild/moderate adverse life events during weeks, months to
few years before the depressive episode. A typical sequence that
triggers depression is: first the patient voluntarily thinks about
the stressors, but later this remembrance became automatic or
involuntarily (independent of the patient’s will) and eventually
the patient becomes clinically depressed. It remains unknown
how the psychological, environmental and biological/genetic
factors interact together with a cognitive style to cause a chronic
hyperactivation of area 25. It has been reported that there
is abnormal brain oscillations in PD such as low-frequency
rhythmic bursting in the basal ganglia (5, 25, 36) that are
similar to epileptic activity. It has also been reported abnormal
brain oscillations between some areas in depressive animals (37).
Furthermore, it was suggested that this epileptiphorm abnormal
oscillation can be an electrophysiologic trait of several neurologic
and psychiatric disorders (26). A possible phenomena that we
call mental kindling-like mechanism (Figure 1A) may cause such
abnormal brain oscillation in some types of depression associated
with significant live events and/or stressors.
DISCUSSION
According to our interpretation of the studies presented above,
we propose that a severe adverse life event, or repetitive
mild/moderate chronic negative life events can initially lead,
at least in part, to conscious and transient hyperactivation
of area 25 and then an automatic/involuntary processing of
this information contribute to its chronic hyperactivation.
From a clinical perspective, depressive patients often have
constant, repetitive, involuntary thoughts that they not regularly
pay attention to. They also say that recent sad life events
triggers the memories of previous sad thoughts and feelings,
which amplify the currents ones. Often, they recognize this
pattern if the clinician asks them what are the content of
their thoughts and feeling, at night when they are in the
bed awaiting to fall asleep, or when they are not occupied
with day to day tasks. Similarly to the kindling experimental
model of epilepsy (38), in which repetitive external electric
brain insults lead to abnormal automatic activity and hence
to seizures/epilepsy, repetitive exposure to sad thought can
lead to self-independent chronic abnormal brain activity and
hence depression (abnormal brain epileptiform-like activity
triggered by repetitive automatic or self-amplifying thoughts
in the areas linked to emotions). However, some patients
exposed to several life stressors do not develop symptoms of
depression. This might be related to a resilience effect. As
an example, Caspi et al. found that patients with the long
allele of the serotonin transporter (causing better serotoninergic
activity) are more resilient to stressful life events and hence
less susceptible to develop depression than patient with the
short allele of the same gene (39). In the context, we can
speculate that life events triggered kindling-like mechanism or
mental kindling-like mechanism will disrupt the neural activity,
in susceptible patients, either locally in some brain areas (such
as the 25) or more broadly in other emotion circuitries.
According to this perspective to understand depression, the
final endpoint of depression could be explained as a brain
dysrhythmia (depressive neural dysrhythmia), either locally (one
nucleus) or systemically (circuitries, different nuclei), in which
genetic and neurochemical mechanism would play important
roles. This perspective that we call integrative perspective to
understand mental disorders (Figure 1B) can integrate different
scientific points of view to understand psychiatric disorders: (1)
Neurosurgery—functional neurosurgery, to ablate the abnormal
area (excision, ablation, applying radiofrequency or the new
electric stimulation approach); (2) Neurology: specific brain areas
have specific functions. Some brain areas are involved in healthy
emotions. A lesion on these areas could cause depression; (3)
Psychiatry and Neuroscience: Monoamine theory. Decreased
serotonin and/or noradrenalin neurotransmission can cause
depression. Treatment of depression can be achieved by restoring
the monoamine neurotransmission, epigenetic, and changes
in brain oscillation. Also specific personalities have specific
cognitive styles that confers susceptibility to specific disorders
(ex. patients with ruminative tendency are prone to depression);
(4) Psychology/psychotherapy: Repetitive mild/moderate life
traumas or severe life trauma can increase the risk of depression.
Applying a new psychological style can help to address and deal
with specific adverse life events.
Although we formulated our opinion based on the
interpretation of recent and relevant scientific data and
clinical studies, we acknowledge that future research will be
needed to test the validity of our proposed model.
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